Research Analysts’ Recent Ratings Updates for Monopar Therapeutics (MNPR)

Several brokerages have updated their recommendations and price targets on shares of Monopar Therapeutics (NASDAQ: MNPR) in the last few weeks:

• 6/14/2026 – Monopar Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/6/2026 – Monopar Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/2/2026 – Monopar Therapeutics was given a new $105.00 price target by Piper Sandler.
• 6/2/2026 – Monopar Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 5/9/2026 – Monopar Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 4/21/2026 – Monopar Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.